News Column

Alopecia Areata: Baldness Reversed With Bone Marrow Drug

August 18, 2014

Maev Kennedy, The Guardian (UK)

Treatment with a drug normally used for a bone marrow condition has completely reversed baldness caused by alopecia in three patients, scientists in the US have announced. The sufferers had lost at least a third of the hair on their heads, and each regained total hair regrowth within five months of being treated with ruxolitinib, which is approved in the US and EU for treatment of myelofibrosis.

One of the team from Columbia University medical centre, Professor Angela Christiano, has herself suffered from the condition, and described it as "not life threatening, but it is life altering".

The results are announced in the online edition of Nature Medicine journal, by the team from Columbia, who previously identified the immune cells responsible for destroying the hair follicles. The treatment would not work for the more common male-pattern baldness, which is linked to hormones.

The scientists tested two drugs known as JAK inhibitors, ruxolitinib and tofacitinib, on mice - where hair loss was completely reversed and the effects proved long lasting - and have now gone on to test ruxolitinib on human patients. Christiano said it was wrong to dismiss the condition as unimportant. "Patients with alopecia areata are suffering profoundly, and these findings mark a significant step forward for them."

Alopecia areata, which typically causes patchy hair loss, is an autoimmune disease where the immune system attacks and destroys the hair follicles.

Of the tiny group of sufferers involved in the clinical trial, all three showed dramatic hair regrowth after treatment with a twice daily tablet for up to five months. The team leader, Raphael Clynes, said: "We've only begun testing the drug in patients, but if the drug continues to be successful and safe, it will have a dramatic, positive impact on the lives of people with this disease."

-----

Original headline: Bone marrow drug found to reverse alopecia



Source: (c) 2014 Guardian Newspapers Limited.


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters